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Introduction
Although IUDs and implants have been around for a
long time, their use has been severely hampered and al-
most extinguished for periods of time due to early de-
sign flaws, difficult insertion and removal demands, or
by the unacceptable side effect profiles. It is all very dif-
ferent now. The currently available LARC methods are
easy to use, safe, long lasting, quickly reversible and 20
times more effective than oral contraceptive pills [1–4]
(Fig. 1). The LARC methods have high patient accept-
ability [5], have limited contraindications for use, and
are often recommended, in some cases, due to their dra-
matically improved bleeding control. All of the LARC
methods can be inserted right after delivery or abortion
and following removal, fertility is rapidly restored. Al-
though the LARC methods have a high up-front cost,
most or all of these costs are often covered by a 3rd
party. In any case, compared to other options, they are
highly cost-effective in the long-term [6–10].
Use of the LARC methods in the U.S. has traditionally
trailed dramatically behind Europe [11], Asia and devel-
oping countries. Worldwide, the IUD is the currently
the most popular means of reversible birth control in
the world with 160 million users (2/3 of the users are in
China) [12]. The good news is that as education and un-
derstanding of these new generations of LARC methods
is getting to U.S. consumers, their popularity has had re-
markable continual growth [13].
Troubled history of long-acting reversible contraceptive
methods
IUD history
The first IUD was reported from Poland in 1909. This
intrauterine ring was modified in 1920-30 by a Germany
scientist and separately by a Japanese physician in1934.
In 1949 another German scientist who had immigrated
to the US developed a stainless steel ring IUD.
The U.S. FDA first approved IUDs in 1968 eventually
bringing the Lippes Loop, the Tatum-T, The Saf-T-Coil,
Gynekoil and Copper 7 to the U.S. market. These IUDs
were made with plastic, allowing the IUD to bend for in-
sertion and then regain its shape. These IUDs also had a
monofilament nylon string added to facilitate removal.
The Lippes Loop, one of the most popular first gener-
ation IUDs, was introduced in the mid 1960’s. From
1960-1970, 12 million women worldwide had IUDs
inserted including 3 million living in the US.
By 1970 there were over 17 IUDs in development
worldwide. With the discovery that the addition of a
copper band to the IUD increased effectiveness, a new
generation of IUDs [Tatum-T and Copper-7] was intro-
duced. Researchers also addressed the bleeding and
cramping problems associated with copper containing
IUDs with a new wave of technology directed at devel-
oping IUDs that released micro-dose progestin. By add-
ing the hormone, these IUDs were noted to decrease
cramping and bleeding by an average of 90 %.
But the popularity and use of all IUDs was soon to be
in serious jeopardy, particularly in the U.S., as a new
IUD with a design flaw was already gaining popularity in
the U.S. market. The Dalkon Shield, designed with fins
to resist expulsion, was introduced in 1968. These fins
had the disadvantage of making removal difficult and a
super-strong multifilament string was added. By 1974,
after over 2.2 million had been sold in the US, A.H.
Robins suspended their sales. Reportedly six women had
died due to complications of the IUD and thousands
more had suffered serious infections. Scientific work
eventually discovered a serious design flaw in the multi-
filament string. Studies using scanning electron micros-
copy reported that all strings that had been removed
from users showed deterioration of the outer sheath and
bacterial contamination of the underlying multifilaments
[14, 15]. This finding is the likely cause of ascending in-
fection seen by so many Dalkon Shield users, resulted
from contamination from either an ascending infection
up the string or from direct contamination when anCorrespondence: donna.shoupe@med.usc.edu
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IUD was pulled into the endometrium as with an on-
going pregnancy [16, 17]. Even though the Dalkon Shield
was the only IUD implicated, the ensuing debacle af-
fected the reputation of all IUDs. By 1986, all but 1 IUD
(Progestasert – manufactured until 2001) was pulled
from the U.S. market. For 2 years the U.S. market for
IUDs almost disappeared.
In 1988 GynoPharma introduced a new copper IUD, the
T-380 A (ParaGard), to the U.S. market. This introduction
started the rebound of IUD use in the U.S. A new hormo-
nal IUD (Mirena) was approved by the FDA in 2000 and
the smaller 3-year version, Skyla, was approved in 2013.
17 The most recent approval from the FDA was on March
2, 2015 for a new IUD that was designed with affordability
in mind. Liletta is very similar to the Mirena although it is
now only approved for 3 years of use. Ongoing studies
should result in a longer approved use.
Due to efforts by public health professionals including
the American College of Obstetrics and Gynecology and
the Centers for Disease Control and Prevention (CDC),
public opinion and use of IUDs has been steadily im-
proving [18–20].
Implant history
Implants have also had their controversies and chal-
lenges. In 1990 the six rods implant (Norplant) was ap-
proved by the U.S. FDA. By 2002 Norplant was taken off
the market due to limitations of product supplies, issues
of coercion in women convicted of drug or child abuse,
as well as issues related to difficult removals [21, 22].
For the next 4 years there were no implants available in
the US. The return of contraceptive implants began in
2006 when the FDA approved the one rod implant
system (Implanon). Clinical trials had shown that the
average insertion time was only one minute and the
average removal time was only 3 minutes. In 2010
Implanon was replaced with the next generation im-
plant, Nexplanon. The newer implant featured an im-
proved, easier to use inserter and the addition of a
barium marker on the implant making it more detect-
able by imaging techniques.
The ongoing efforts of large numbers of public
health professionals, national organizations, and
healthcare providers to educate the public on the
safety and efficacy of the LARC methods has bene-
fited both IUDs and the implant [18–20, 23–28].
While the popularity of the implant is still lagging be-
hind the rapid increases seen in IUD use, implant de-
mand is steadily climbing.
Updated guidelines now encourage the use of LARCs in
all age groups
In 2009, LARC methods became first-line options when
the American College of Obstetricians and Gynecolo-
gists recommended LARC methods for the majority of
women [29]. Since then the growing support had been
clear and wide-spread. The CDC Eligibility Criteria for
Contraceptive Use recommends LARC methods for the
majority of women who have their first menses, regard-
less of whether they have had any pregnancies [11]. The
American Academy of Pediatrics recommends LARC
methods for adolescents as “prevention is the corner-
stone of pediatric practice” [20]. A recently published
article in Pediatrics: the Official Journal of the American
Academy of Pediatrics stated “We suggest that in re-
sponse to the improvement in the effectiveness and
Fig. 1 Perfect vs Typical Use LARCs
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safety of long-acting reversible contraceptive (LARC’s:
i.e. IUD and implants ), pediatricians have a special
opportunity to prevent unintended pregnancy” [30].
ACOG revised one of their practice guidelines on
LARCs in 2012. The new guidelines recommended that
sexually active adolescents at high risk for unintended
pregnancy should be encouraged to consider LARCs
[27]. In its Family Planning Handbook for Providers,
WHO recommends the implants and IUDs for women
with or without children of any age, including adoles-
cents and women over 40 [28]. In an editorial in the
Association for Reproductive Health Professional’s
Contraceptive Journal, the authors decry the “outdated
perceptions about appropriate patient candidates for
LARC among health care providers continue to nega-
tively impact their use.” An emerging body of research
has disproved a number of contraindications to IUC use.
Specifically women of any age or parity and those who
are postpartum or post first or second trimester abortion
are eligible for IUC [31].
Efforts to increase LARC use in young women
Public health professionals have recently been develop-
ing programs to increase knowledge and use of LARC
methods among young women. The Contraceptive
CHOICE project was conducted by researchers at
Washington University in Saint Louis. These researchers
noted the high rates of unintended pregnancies and
abortions in the U.S. including 273,105 babies born to
teens 15–19 in 2013 [32]. Their goal was to eliminate
cost barriers and increase patient access to LARC
methods particularly in young women in their region.
The CHOICE researchers developed a standardized
script that included tiered counseling (most effective
methods first) of all reversible methods. The “menu of
options” listed hormonal IUD first, followed by the cop-
per IUD and implant, then injections, pills, patch, vagi-
nal ring, condoms and lastly emergency contraception.
In their overall cohort 75 % of patients chose LARC
methods while 72 % of teens opted for LARC methods.
The overall 12 month continuation rate of the LARC
methods was 86 % (with the LNG-IUS with the highest
continuation rate 87.5 %). All of the other methods had
56–49 % twelve month continuation rate. The satisfac-
tion rate in the overall cohort was 78–85 % in the LARC
methods and between 54–44 % for the other method.
In the 14–19 year old group, satisfaction was between
74–77 % for the LARC methods and between 31–46 %
for the other methods [33, 34].
These researchers projected that if the CHOICE model
was adopted nationally among all sexually active teens in
the U.S., the pregnancy rate of 67.8 per 1,000 teens (in
2008) [33] could be reduced to 29.6. [33, 34] Confirm-
ation of this assertion was a recent paper showing
reductions in teenage pregnancy and abortion rates in
England as LARC usage increases [35].
Overall use
According to the Guttmacher Institute, the use of LARC
methods has in the U.S. has jumped to 12 %, “the high-
est ever recorded” [36]. While the overall use of contra-
ceptive use in reproductive-aged women has not
changed, the newer data shows an ongoing shift towards
the LARC methods. For comparison, in 2002 only 2.4 %
of contraceptive users relied on LARC methods and in
2007, this number was 8.5 %. The top methods of choice
are the OCPS (26 %) followed by the condom (15 %)
and now LARC methods (12 %) [36].
The good news behind this upward trend of LARC use
is the accompanying downward slope of unwanted preg-
nancies in the U.S. and 13 % decline in abortions be-
tween 2008 and 2011 [36]. CDC data reporting
increased long-term use of LARC methods is coupled
with data showing declines in overall births and abor-
tions. The Affordable Care Act (ACA) that guarantees
coverage of contraceptives for most women, including
LARC methods, had been instrumental in the dramatic
increase in LARC use. Protecting this funding source is
a priority if this downward trend in unintended preg-
nancy rates in the US is to continue. Other areas of pri-
ority include Title X, Medicaid, and extension of the
ACA into all states [36, 37].
Worldwide use
Worldwide use of contraceptives shows uneven pro-
gress. Most developing countries have generally seen
consistent growth of contraceptive use, particularly
the more effective methods, while in others, such as
Nepal and Jordan, the use has leveled off or even
fallen slightly. In many of the less and least developed
countries there are large unmet needs for family plan-
ning [38, 39].
It is interesting, however, to compare the use of mod-
ern methods, particularly LARC use in countries around
the world (compiled in 2013). There is a great deal of
variation of contraceptive use worldwide with high un-
met needs among young unmarried women especially in
less developed poorer countries.
Effectiveness
LARC methods are around 20 times more effective than
any other type of reversible birth control excluding the
DMPA injection [1–3]. In a 2012 study of over 7400 par-
ticipants, the failure rates in participants using oral
contraceptive pills, birth control patch, or the vaginal
ring was 17-20 times higher than the risk of those using
LARC methods. For those under 21 using the pills,
patch or ring, the risk of failure was almost twice as high
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as the older participants. But rates of unintended preg-
nancy regardless of age remained low in the LARC (and
depo-provera group) [1].
Contraindications
For common conditions, there are very few contrain-
dications to LARC methods. ACOG endorses the US
Medical Eligibility Criteria from the CDC which re-
port the following contraindications. Contraindications
to insertion of any IUD is the presence of cervicitis,
current chlamydial infection or gonorrhea, distorted
uterine cavity, current PID, cervical cancer awaiting
treatment, suspicious (for serious disease) unexplained
vaginal bleeding, puerperal sepsis, pregnancy, gesta-
tional trophoblastic disease, AIDS (category 3 -risks
may outweigh benefits), complicated organ transplant
(category 3), hepatocellular adenoma or malignant
liver tumor (3) [40].
Contraindications for the hormonal IUD are history
or current breast cancer, severe decompensated
cirrhosis, SLE with positive or unknown
antiphospholipid antibodies (category 3).
Contraindication for copper IUD insertion is severe
thrombocytopenia (category 3), [40]
Implants also have few contraindications, including
history or current breast cancer, severe decompensated
cirrhosis, suspicious for serious cause unexplained vagi-
nal bleeding (category 3 , SLE with positive or unknown
antiphospholipid antibodies (category 3), hepatocellular
adenoma or malignant liver tumor (category 3) The
bleeding pattern after implant insertion is most com-
monly less bleeding or similar bleeding but in a small
percentage of women, heavier, unpredictable bleeding
may occur [40].
Importantly, IUDs and Implant can be used in the fol-
lowing conditions [40]:
 Insertion in presence of inflammatory bowel disease,
 current history of ischemic heart disease
 multiple risk factors for arterial CV disease
 ovarian cancer





 valvular heart disease
 fibroids
 anticoagulation therapy
 most antiretroviral therapy
 antimicrobial therapy
 sickle cell disease
 DVT/PE established on anticoagulant therapy for
3 months
 family history DVT/PE
 major surgery
 depressive disorders
 diabetes with or without vascular disease
 migraines with or without aura
 HIV infected or high risk for getting HIV
 The copper IUD can be used in women after breast
cancer
Counseling: risks and benefits
The currently available LARC methods are safe, easy to
use, long lasting, quickly reversible and 20 times more
effective than oral contraceptive pills [1–4]. The LARC
methods have high patient acceptability, 5 and generally
have few contraindications for use [40]. The hormonal
IUD is associated with dramatic reductions in bleeding,
often amenorrhea, reduced cramping and reduced pain
associated with endometriosis. All of the LARC methods
can be inserted right after delivery or abortion and fol-
lowing removal, fertility is rapidly restored. Although the
LARC methods have a high up-front cost, most or all of
these costs are often covered by a 3rd party. In any case,
compared to other options, they are highly cost-effective
in the long-term [6–10].
Importantly, modern IUDs do not carry a risk of
pelvic infection after the first 20 days after insertion
[2–41]. There is a very small risk of uterine perfor-
ation (much less common than in the past due to ad-
vanced IUD designs), or expulsion. Heavier bleeding
is a side effect of the copper-IUD while a dramatic
reduction in menses is a benefit of the hormonal
IUD. A small percentage of women with the hormo-
nal IUD may experience progestin side effects such a
mood changes or increased acne [42].
Contraceptive implants generally reduce bleeding and
a complete cessation of menstrual flow can occur. How-
ever, some women may experience irregular and/or in-
creased bleeding. Progestin side effects are not common
with the implant but may include increased acne or
mood changes [43, 44].
Future directions: identifying barriers and increasing
LARC Use
The preceding discussion has provided evidence that
LARC methods are safe, reversible, have high patient
acceptability, and very few contraindications. Newer
generation LARCs, such as the levonorgestrel contain-
ing IUDs, also have non contraceptive benefits. Per-
haps most importantly, these methods are 20 times
more effective than oral contraceptive pills [1–4].
Despite the numerous demonstrated advantages of
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LARCs, uptake remains low in the U.S. and many
countries throughout the world (Table 1). In the fol-
lowing section, Future Directions, we will examine
the barriers to LARC use and identify current and
potential strategies for increasing LARC uptake and
adherence.
There are multiple barriers to LARC use [45, 46]. Some
of these barriers are global in nature and some of them
are unique to specific populations such as post-partum
women, minority and low-income women or geographic
locations which are resource limited [47, 48]. A knowledge
deficit about LARCs exists among many healthcare pro-
fessionals. This lack of education and training may result
in significant barriers to LARC access that are linked to
the provider or pharmacist [49]. In a recent American
College of Obstetricians and Gynecologists Practice Bul-
letin some of the primary barriers to LARC use cited in-
cluded cost, provider experience, and interest, as well as
patient interest [50] (Table 2).
Cost
Women living in poverty have higher rates of unin-
tended pregnancy as well as abortion [51, 52]. The
CHOICE study clearly demonstrated that unintended
pregnancy rates can be dramatically reduced by eliminat-
ing financial barriers. When cost is not a factor this
study found that 75 % of eligible women chose a LARC
method [53]. Although multiple studies have shown that
investment in contraception leads to significant cost-
savings, access to LARC methods by poor women re-
mains challenging. In a frequently cited publication by
Trussell et al, a decision model was used to evaluate cost
of contraceptive methods from a payer perspective. The
study results demonstrated that the use of any contra-
ceptive method resulted in cost-savings compared to use
of no method. This included LARCs, which despite a
higher upfront cost, are more cost effective as a result of
their high efficacy [54].
Foster et al provided additional support for the find-
ings of Trussell and colleagues in their study of a
California Medicaid amendment. The California Family
Planning, Access, Care, and Treatment (Family PACT),
is a Medicaid State Plan Amendment that serves more
than 1.8 million clients per year at or below 200 % of
the federal poverty level. The authors found that public
cost-savings for each dollar spent on contraception
ranged from $1.58 for barrier methods to approxi-
mately $5 for LARC methods. Short-term hormonal
methods and DMPA demonstrated intermediate cost-
savings resulting in cost savings from $2.12 for the
patch to $4.00 with DMPA, Most significantly this
study demonstrated use of LARC methods is cost-
effective even if methods are not used for their full du-
rations of efficacy [55].
Provider interest, knowledge and training
Multiple authors have shown that provider beliefs and
practices pose a significant barrier to the widespread use
of LARCs. An ACOG supported survey of fellows dem-
onstrated that even when providers consider it appropri-
ate to provide LARCs, a much smaller percentage of





WORLD 57 % 13 %
Africa 27 % 5 %
South
America
71 % 5 %
Asia 61 % 17 %
Asia excluding
China
48 % 6 %
Eastern
Europe




67–74 % 8–22 %
Northern
Europe
82 % 13 %
Australia 68 % 4 %
Vietnam 60 % 32 %
North Korea 58 % 42 %
South Korea 70 % 12 %
UK 84 % 11 %
China 84 % 40 %
Syria 33 % 20 %
Egypt 57 % 36 %
Cuba 73 % 25 %
Canada 72 % 1 %
USA 73 % 6 %
Adapted from Family Planning Worldwide 2013 Ref 38
Table 2 Barriers to LARC Use
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providers actually offer them in practice. The vast major-
ity of obstetrician gynecologists offer IUDs (95.8 %), but
a majority require two or more visits, which is a poten-
tial barrier to more wide spread use. Although 67 % of
respondents felt it was appropriate to offer IUDs after
spontaneous or therapeutic abortion, only 10.9 % offered
them to patients. Nearly half (43.5 %) of fellows surveyed
thought it was appropriate to offer IUDs in the immedi-
ate postpartum period, only 7.2 % offered this method to
patients (Table 3) [56].
Education and training is a significant predictor of the
use of LARCs. A lack of training, particularly training
during residency, is an important barrier to the use of
these contraceptives. Nearly a third of obstetrician gyne-
cologists who were surveyed reported a lack of insertion
training as a barrier to the use of contraceptive implants.
Although a large majority (92 %), reported IUD insertion
training during residency, only 50 % reported training
on implants. Continuing education within the past two
years was, in fact, the best predictor of implant
provision. This is critically important because as the au-
thors point out, “clinicians are gatekeepers of LARC
services” [56].
Patient interest
Patient interest is a critical factor in increasing LARC
uptake. The CHOICE study provided clear evidence that
patient interest in LARCs can be dramatically increased
with education and reduction of economic barriers. 1
When obstetrician gynecologists were surveyed about
the use of contraceptive implants, 46 % cited lack of pa-
tient interest as the reason for not offering this method
[56]. In a study of predictors of LARC use among un-
married young adults, women with high IUD knowledge
were six times more likely to be current LARC users
(OR 6.3). High IUD knowledge was the strongest pre-
dictor of LARC use in the adjusted model [57].
Age is also an important predictor of interest in
LARCs. Women ages 18–19 are less likely to report
current LARC use compared with 25–29 year olds (OR
0.1 confidence interval 0.02-0.4) [57]. This statistic high-
lights the important role of adolescent health care pro-
viders in encouraging the use of LARCs in younger
women. In a study of adolescent health care providers
residency training in obstetrics and gynecology or family
medicine was the strongest predictor of LARC provision,
especially IUDs [58]. Education and training in LARC
procedures appears to be an important factor in the pro-
vider’s role in encouraging interest in LARCs. Provider
knowledge appears to be a prerequisite for patient edu-
cation about LARCs [58].
Strategies for increasing LARC use
The increased uptake of LARCs has the potential to be
an important strategy to decrease the unintended preg-
nancy rate. Multiple clinical studies have indicated that
enhanced access to these methods has a dramatic impact
[1, 2, 7]. In the following section strategies to increase
LARC access and use will be discussed.
Reducing cost
An important consideration in evaluating the cost of
LARCs is documentation of the cost savings associ-
ated with these methods, and not just the upfront
cost of the contraceptive. In a recent article in the
N.Y. Times the author examined the remarkable suc-
cess of the Colorado state effort to reduce teen preg-
nancies. The article reported that the state health
department estimated that every dollar spent on the
long-acting birth control initiative saved $5.85 for the
state’s Medicaid program, which covers more than
three-quarters of teenage pregnancies and births [7].
Multiple scientific manuscripts have also documented
the cost-effectiveness of these methods [54, 55]. Cost
analysis studies that have assessed the cost benefit of
contraception have nearly universally found that
contraception, particularly highly effective contracep-
tion, is cost effective. Studies by the Guttmacher In-
stitute found that for every dollar spent on family
planning services, $1.30 would be saved on maternal
and newborn health care [59]. It is critical that part
of the advocacy process for LARCs includes education
of those involved in healthcare related legislation and
healthcare services.
Another important strategy is the reduction of cost
through large scale purchases. The Department of
Defense healthcare services and large HMOs such as
Kaiser Permante, as well as non-governmental organiza-
tions (NGOs) such as the Bill and Melinda Gates Foun-
dation illustrate the potential to reduce LARC costs
when these drugs and devices are bought in bulk. More
than 200 million patients in the U.S. receive their health
care through managed care organizations. This statistics
illustrates the important role of managed care pharma-
cies in securing lower drug and device prices. HMOs
have the ability to negotiate volume discounts, which re-
sults in lower drug expenditures and greater profits for
the HMOs. These cost savings can be achieved in a
Table 3 Provider Beliefs and Practices
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number of ways including, discount off invoice or bulk
discounts, and rebate agreements [60]. Prescription drug
coverage is one of the ten essential benefits required by
the Affordable Health Care Act. Because the ACA makes
drug coverage a core part of health insurance, it elimi-
nates the insurers’ ability to tack on a prescription drug
benefit plan to a health care plan at an additional cost.
As a part of preventative care, prescription birth control
is now free if generic, and available through a co-pay if
brand name [61].
Increasing provider interest, knowledge and training
Although the majority of gynecologists have training in
IUD insertion, a smaller percentage have training in im-
plant insertion, and many who have training do not have
adequate knowledge of patient eligibility [62, 63]. The
American College of Obstetricians and Gynecologists
(ACOG) has created a number of programs to enhance
provider education. ACOG provides a list of LARC Clin-
ical Training Opportunities as a LARC Slide Set and a
LARC for Adolescents Slide Set. The organization also
provides a list of Family Planning Speakers with special
expertise in LARCs [62].
Family physicians also provide a great deal of the
contraceptive counseling and provision in the U.S. Al-
though the vast majority of family physicians believe pa-
tients are receptive to learning about IUDs, one study
found that less than half offer counseling or the method.
Both gynecologists and family physicians were found to
have inadequate knowledge of IUD eligibility as gauged
by the CDC and Prevention Medical Eligibility Criteria
for contraception. Family physicians did report an inter-
est in updating contraceptive skills. There is clearly an
opportunity to increase LARC uptake through training
and education of physician providers [63].
Nurse practitioners are often the primary providers of
contraception for a number of women. It is important
that women’s health nurse practitioners are trained not
only in contraceptive counseling, but also in IUD inser-
tion. In a study of LARC counseling and provision by
women’s health nurse practitioners, two thirds (66 %),
were trained in IUD insertion. This compared to only
12 % of primary care nurse practitioners. Contraceptive
counseling, however, included IUDs in 43 % of cases.
Nurse practitioners were found to use overly restrictive
patient eligibility criteria which was inconsistent with
the CDC guidelines. Both insertion training and know-
ledge of patient eligibility were significantly associated
with IUD provision. Contraceptive implant provision
was also low, with only 42 % of NPs in women’s health
and 10 % of primary care NPs providing implants to
their patients [64]. Increasing training and education for
nurse practitioners who provide contraception will play
a critical role in increasing LARC usage as healthcare
reforms focused on affordable primary care are put into
practice.
Pharmacists are becoming important providers of
contraceptive services, but they are often not considered
as advocates for increasing LARC uptake. For a number
of years pharmacists have provided emergency contra-
ception. Now that emergency contraception is available
over the counter, patients are more likely to look to
pharmacists for medical advice. Women who seek
emergency contraception provide an opportunity for
pharmacists to provide LARC education and referrals.
Pharmacists, as providers of emergency contraception,
are well positioned to intervene with patients at high
risk for unintended pregnancy. Both the American
College of Clinical Pharmacy (ACCP) and the Women’s
Health Practice and Research Network (PRN) advocate
an expanded role for pharmacists in advocating for and
facilitating the use of LARC methods [65].
Increasing patient interest
The CHOICE study is a model of increasing patient
interest and LARC use through patient education.
Through the development of a standardized script that
included tiered counseling [most effective methods first]
of all reversible methods, LARC usage in this study was
markedly increased. The investigators found 75 % of pa-
tients chose LARC methods while 72 % of teens opted
for LARC methods. The overall 12 month continuation
rate of the LARC methods was very high at 86 %. The
satisfaction rate was also high at 78–85 % in the LARC
methods compared to 54–44 % for the other methods.
Among adolescents the satisfaction rate was between
74–77 % for the LARC methods and between 31–46 %
for the other methods [33, 34].
To successfully increase LARC uptake outside the set-
ting of a clinical trial, other strategies for increasing pa-
tient education and interest must be identified. In a
study from the United Kingdom examining the etiology
of low uptake of LARCs, the authors identified dissemin-
ation of information in multiple venues such as health
centers, schools, peer education, as well as the use of
multiple media forms. Increasing primary healthcare
nurses’ role in contraceptive counseling and provision
was also considered an important strategy [65].
Conclusions
The safety, convenience and ability of LARC use to im-
pact high rates of unintended pregnancy have been doc-
umented in numerous clinical trials as well as in health
care settings that provide increased access to these
methods [1, 2, 7]. The challenges to increase LARC up-
take are many and include decreasing costs, insuring
easy access to training, providing increased patient
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knowledge and encouraging patient interest. Overcoming
these barriers requires a multifaceted strategy which
involves patients, providers, healthcare administrators,
legislators and the community.
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